ANAB - AnaptysBio Inc Stock Price, Fair Value and News

$20.45+0.11 (+0.54%)

Delayed as of 21 Nov 2024, 09:55 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ANAB Price Action

Last 7 days

-2.0%

Last 30 days

-42.5%

Last 90 days

-45.4%

Trailing 12 Months

43.5%

ANAB RSI Chart

ANAB Valuation

Market Cap

618.9M

Price/Earnings (Trailing)

-3.74

Price/Sales (Trailing)

11.57

EV/EBITDA

-2.7

Price/Free Cashflow

-5.99

ANAB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ANAB Fundamentals

ANAB Revenue

Revenue (TTM)

53.5M

Rev. Growth (Yr)

518.4%

Rev. Growth (Qtr)

173.6%

ANAB Earnings

Earnings (TTM)

-165.7M

Earnings Growth (Yr)

11.95%

Earnings Growth (Qtr)

29.59%

ANAB Profitability

EBT Margin

-297.33%

Return on Equity

-196.35%

Return on Assets

-33.57%

Free Cashflow Yield

-16.7%

ANAB Investor Care

Shares Dilution (1Y)

14.50%

Diluted EPS (TTM)

-6.08

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	20.8M	28.3M	53.5M	0
2023	11.3M	13.7M	16.3M	15.0M
2022	50.0M	36.7M	23.5M	10.3M
2021	71.2M	101.3M	122.2M	63.2M
2020	23.0M	18.0M	18.0M	75.0M
2019	0	7.5M	10.0M	8.0M
2018	0	0	3.3M	5.0M
2017	0	18.8M	13.0M	1.6M
2016	17.3M	17.1M	16.9M	16.7M
2015	0	0	0	17.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

CEO	Mr. Daniel R. Faga
WEBSITE	anaptysbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	96

AnaptysBio Inc Frequently Asked Questions

What is the ticker symbol for AnaptysBio Inc? What does ANAB stand for in stocks?

ANAB is the stock ticker symbol of AnaptysBio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AnaptysBio Inc (ANAB)?

As of Wed Nov 20 2024, market cap of AnaptysBio Inc is 618.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANAB stock?

You can check ANAB's fair value in chart for subscribers.

Is AnaptysBio Inc a good stock to buy?

The fair value guage provides a quick view whether ANAB is over valued or under valued. Whether AnaptysBio Inc is cheap or expensive depends on the assumptions which impact AnaptysBio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANAB.

What is AnaptysBio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, ANAB's PE ratio (Price to Earnings) is -3.74 and Price to Sales (PS) ratio is 11.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANAB PE ratio will change depending on the future growth rate expectations of investors.